Profil
Dr. Michael Beckert, MD MBA, was Chief Medical Officer at Ascendis Pharma A/S.
Dr. Beckert was previously employed as Chief Medical Officer & Executive Vice President by LifeCycle Pharma A, Medical Director by SkyePharma Plc, and Chief Medical Officer by Scil Biomedical GmbH.
He received his MBA from Donau-Universität Krems and a doctorate degree from Freie Universität Berlin.
Ehemalige bekannte Positionen von Michael Beckert
| Unternehmen | Position | Ende |
|---|---|---|
| ASCENDIS PHARMA A/S | Technik-/Wissenschafts-/F&E-Leiter | 26.02.2016 |
| VELOXIS PHARMACEUTICALS A/S | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2008 |
| SKYEPHARMA PLC | Corporate Officer/Principal | 01.01.2004 |
Scil Biomedical GmbH
 Scil Biomedical GmbH Pharmaceuticals: MajorHealth Technology Scil Biomedical GmbH provides pharmaceutical preparations. The private company is based in Munich, Germany. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
Ausbildung von Michael Beckert
| Freie Universität Berlin | Doctorate Degree |
| Donau-Universität Krems | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ASCENDIS PHARMA A/S | Health Technology |
| Private Unternehmen | 3 |
|---|---|
SkyePharma Plc
 SkyePharma Plc Pharmaceuticals: OtherHealth Technology SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom. | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
Scil Biomedical GmbH
Scil Biomedical GmbH Pharmaceuticals: MajorHealth Technology Scil Biomedical GmbH provides pharmaceutical preparations. The private company is based in Munich, Germany. | Health Technology |
